Blood platelet volume predicts treatment-specific outcomes of metastatic castration-resistant prostate cancer.

Wataru FukuokayaTakahiro KimuraFumihiko UrabeShoji KimuraKojiro TashiroShunsuke TsuzukiYusuke KoikeHiroshi SasakiKenta MikiShin Egawa

Published in: International journal of clinical oncology (2020)

The present study identified pretreatment MPV as a significant treatment-specific prognostic factor of PSA and radiographic progression in patients with mCRPC who received first-line treatment. Furthermore, our results suggested that those with small MPV may better be treated initially with docetaxel than ARAT.

Keyphrases

prognostic factors
small cell lung cancer
type diabetes
adipose tissue
combination therapy
metabolic syndrome
skeletal muscle